EUVIMEDEUVIMED entdecken
Crossref

Inhibition of angiogenesis in the management of refractory gastrointestinal bleeding in patients with LVAD support

Sara S Inglis iD, Rabea Asleh, Vivek N Iyer, Sarah D Schettle iD, Philip J Spencer, Mauricio A Villavicencio, Richard J Rodeheffer, Sudhir S Kushwaha, Atta Behfar, Andrew N Rosenbaum iD

Artificial Organs · 2024

DOI: 10.1111/aor.14694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2024. Verfasst von Sara S Inglis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Gastrointestinal Hemorrhage, Angiogenesis Inhibitors, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastrointestinal bleeding (GIB) in patients with continuous flow left ventricular assist devices (CF‐LVADs) is often related to GI angiodysplasia (GIAD). We previously reported data on VEGF inhibition with IV bevacizumab in the treatment of LVAD‐associated GIAD bleeding, and now present follow‐up data on patients treated with IV bevacizumab and/or low‐dose oral pazopanib.

Methods

All consecutive adult patients with LVAD‐associated GIB from GIAD treated with bevacizumab or pazopanib, from July 20, 2017 to June 22, 2022, were included in the analysis. Data on hospitalizations, GI endoscopic procedures, and blood transfusions were obtained from first admission for GIB up to a median of 35.7 months following treatment initiation (range 1.3–59.8 months).

Results

Eleven patients (91% male, mean 69.5 ± 8.9 years) were included. Eight patients (73%) received IV bevacizumab, two patients (18%) received oral pazopanib, and one patient (9%) received bevacizumab followed by pazopanib therapy. We observed a significantly decreased number of annualized hospitalizations for GIB (median difference − 2.87, p = 0.002), blood transfusions (median difference − 20.9, p = 0.01), and endoscopies (median difference − 6.95, p = 0.007) in patients pre‐ and post‐anti‐angiogenic therapy (bevacizumab and/or pazopanib). Similarly, a significant improvement in these clinical outcomes was noted in the bevacizumab group with decreased annualized hospitalizations (median difference − 2.75, p = 0.014), blood transfusions (median difference − 24.5, p = 0.047), and number of endoscopies (median differences −6.88, p = 0.006).

Conclusion

Anti‐angiogenic therapy with IV bevacizumab and/or low‐dose oral pazopanib appears to provide benefits in patients with LVAD‐associated GIB with reduced hospitalizations, blood transfusions, and need for GI endoscopic procedures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesGastrointestinal HemorrhageAngiogenesis InhibitorsPyrimidinesBevacizumabSulfonamidesIndazolesHumansMaleFemaleAgedMiddle AgedRetrospective StudiesTreatment OutcomeAngiogenesis

Stichwörter der Autor:innen

LVADangiodysplasiaangiogenesisgastrointestinal bleeding

Substanzen

Angiogenesis InhibitorsPyrimidinesBevacizumabSulfonamidesIndazolespazopanib

Autor:innen und Institutionen

  • Van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Sara S Inglis, Sarah D Schettle, Andrew N Rosenbaum

Zitieren

APA

Inglis, S. S., Asleh, R., Iyer, V. N., Schettle, S. D., Spencer, P. J., Villavicencio, M. A., Rodeheffer, R. J., Kushwaha, S. S., Behfar, A., & Rosenbaum, A. N. (2024). Inhibition of angiogenesis in the management of refractory gastrointestinal bleeding in patients with LVAD support. Artificial Organs. https://doi.org/10.1111/aor.14694

Vancouver

Inglis SS, Asleh R, Iyer VN, Schettle SD, Spencer PJ, Villavicencio MA, et al. Inhibition of angiogenesis in the management of refractory gastrointestinal bleeding in patients with LVAD support. Artificial Organs. 2024. doi:10.1111/aor.14694

BibTeX
@article{Inglis2024,
  author = {Inglis, Sara S and Asleh, Rabea and Iyer, Vivek N and Schettle, Sarah D and Spencer, Philip J and Villavicencio, Mauricio A and Rodeheffer, Richard J and Kushwaha, Sudhir S and Behfar, Atta and Rosenbaum, Andrew N},
  title = {Inhibition of angiogenesis in the management of refractory gastrointestinal bleeding in patients with LVAD support},
  journal = {Artificial Organs},
  year = {2024},
  doi = {10.1111/aor.14694}
}
Kostenlos starten →